Repositioning Candidate Details
| Candidate ID: | R0731 |
| Source ID: | DB05198 |
| Source Type: | investigational |
| Compound Type: | small molecule |
| Compound Name: | CYC116 |
| Synonyms: | -- |
| Molecular Formula: | -- |
| SMILES: | -- |
| DrugBank Description: | CYC116 is a novel anticancer compound with a unique target profile involving both cell cycle and angiogenesis inhibition mechanisms. In preclinical studies, CYC116 has demonstrated antitumor activity in both solid tumors and hematological cancers. Cyclacel's small molecule investigational drug, CYC116, is the third orally-available Cyclacel drug to enter development, which demonstrated anticancer activity with a mechanism consistent with inhibition of Aurora kinase. |
| CAS Number: | -- |
| Molecular Weight: | |
| DrugBank Indication: | Advanced solid tumors |
| DrugBank Pharmacology: | -- |
| DrugBank MoA: | Aurora kinases are enzymes that help dividing cells share their materials between two daughter cells. In many people with cancer Aurora kinase malfunctions and normal control of cell division is lost resulting in abnormal growth. CYC116 inhibits Aurora kinase may slow down the growth of cancer cells and lead to their death by apoptosis. |
| Targets: | Aurora kinase A; Vascular endothelial growth factor receptor 2 |
| Inclusion Criteria: | Therapeutic strategy associated |
